ASH 2021 | An analysis of the FLAIR trial: sudden cardiac death in patients with CLL
Peter Hillmen
• 13 Dec 2021
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, University of Leeds, Leeds, UK, presents some data from an ad-hoc analysis on the FLAIR trial (ISRCTN01844152), which aimed to evaluate sudden cardiac death observed in patients with chronic lymphocytic leukemia (CLL) being treated with fludarabine, cyclophosphamide and rituximab (FCR) therapy or ibrutinib plus rituximab (IR) therapy. In this analysis, Dr Hillmen explains the variables that were evaluated, that sudden cardiac death was associated with prior history of hypertension or cardiac disease, and how this information can benefit the future monitoring of patients with CLL. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
